In 2025, the company reported a slight 0.21% YoY revenue decline, reflecting portfolio dynamics: Eliquis ($14.44B) continues to anchor the business with strong demand in anticoagulation, Opdivo ($10.04B) remains a cornerstone in immuno-oncology across multiple indications, and Orencia ($3.7B) provides steady growth in immunology, partially offset by pressures from legacy products
When the normal digestive timing is altered, it may affect how the intestines process food components
For patients with pre-existing diabetic retinopathy, ophthalmologic follow-up is recommended, particularly during periods of rapid glycemic improvement
What can make diarrhea worse while taking GLP-1 drugs
That said, competition is coming: Pfizers cotadutide (dual agonist) is in late-stage trials, and if approved, could eat into Lillys share
Bear in mind that researchers still dont know exactly how common these effects are, but studies suggest GLP-1s may affect taste perception
